{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T01:49:31Z","timestamp":1794620971641,"version":"4.9.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:00:00Z","timestamp":1702598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:00:00Z","timestamp":1702598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1038\/s41584-023-01066-5","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T15:02:47Z","timestamp":1702652567000},"page":"73-74","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Emerging therapeutic options for refractory gout"],"prefix":"10.1038","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9301-8941","authenticated-orcid":false,"given":"Kanon","family":"Jatuworapruk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3105-6122","authenticated-orcid":false,"given":"Worawit","family":"Louthrenoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,15]]},"reference":[{"key":"1066_CR1","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/art.41247","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald, J. D. et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Rheumatol. 72, 879\u2013895 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"1066_CR2","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/art.42335","volume":"75","author":"JK Botson","year":"2023","unstructured":"Botson, J. K. et al. A randomized, placebo-controlled study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase: primary efficacy and safety findings. Arthritis Rheumatol. 75, 293\u2013304 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"1066_CR3","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/acr2.11578","volume":"5","author":"JK Botson","year":"2023","unstructured":"Botson, J. K. et al. A randomized, double-blind, placebo-controlled multicenter efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase: 12-month findings. ACR Open Rheumatol. 5, 407\u2013418 (2023).","journal-title":"ACR Open Rheumatol."},{"key":"1066_CR4","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40744-023-00546-0","volume":"10","author":"A Kivitz","year":"2023","unstructured":"Kivitz, A. et al. Phase 2 dose-finding study in patients with gout using SEL-212, a novel PEGylated uricase (SEL-037) combined with tolerogenic nanoparticles (SEL-110). Rheumatol. Ther. 10, 825\u2013847 (2023).","journal-title":"Rheumatol. Ther."},{"key":"1066_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead333","author":"HSB Baraf","year":"2023","unstructured":"Baraf, H. S. B. et al. The COMPARE head-to-head, randomised-controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR\u2122) versus pegloticase for refractory gout. Rheumatology https:\/\/doi.org\/10.1093\/rheumatology\/kead333 (2023).","journal-title":"Rheumatology"},{"key":"1066_CR6","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1002\/art.42447","volume":"75","author":"R Terkeltaub","year":"2023","unstructured":"Terkeltaub, R., Lee, J., Min, J., Shin, S. & Saag, K. G. Serum urate-lowering efficacy and safety of tigulixostat in gout patients with hyperuricemia: a randomized, double-blind, placebo-controlled, dose-finding trial. Arthritis Rheumatol. 75, 1275\u20131284 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"1066_CR7","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","volume":"378","author":"WB White","year":"2018","unstructured":"White, W. B. et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N. Engl. J. Med. 378, 1200\u20131210 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1066_CR8","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.7326\/M23-0724","volume":"176","author":"N McCormick","year":"2023","unstructured":"McCormick, N. et al. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for recurrent gout flares and gout-primary emergency department visits and hospitalizations : a general population cohort study. Ann. Intern. Med. 176, 1067\u20131080 (2023).","journal-title":"Ann. Intern. Med."},{"key":"1066_CR9","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.30885","volume":"6","author":"J Wei","year":"2023","unstructured":"Wei, J. et al. Gout flares and mortality after sodium-glucose cotransporter-2 inhibitor treatment for gout and type 2 diabetes. JAMA Netw. Open. 6, e2330885 (2023).","journal-title":"JAMA Netw. Open."},{"key":"1066_CR10","doi-asserted-by":"publisher","DOI":"10.1177\/20406223221083509","author":"ASY Yip","year":"2022","unstructured":"Yip, A. S. Y. et al. Effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on serum urate levels in patients with and without diabetes: a systematic review and meta-regression of 43 randomized controlled trials. Ther. Adv. Chronic. Dis. https:\/\/doi.org\/10.1177\/20406223221083509 (2022).","journal-title":"Ther. Adv. Chronic. Dis."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-01066-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-01066-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-01066-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T14:03:33Z","timestamp":1706623413000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-01066-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,15]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["1066"],"URL":"https:\/\/doi.org\/10.1038\/s41584-023-01066-5","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,15]]},"assertion":[{"value":"15 December 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.J. is a co-investigator in the EURELIA2 study (NCT05586971), sponsored by LG Chem. W.L. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}